Galera Therapeutics (NASDAQ:GRTX) & Galectin Therapeutics (NASDAQ:GALT) Critical Survey

Galectin Therapeutics (NASDAQ:GALT) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Galectin Therapeutics and Galera Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	0	0	1	0	3.00
Galera Therapeutics	0	0	0	0	N/A

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 283.28%. Given Galectin Therapeutics’ higher probable upside, research analysts clearly believe Galectin Therapeutics is more favorable than Galera Therapeutics.

Earnings and Valuation

This table compares Galectin Therapeutics and Galera Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$41.07 million	($0.74)	-3.88
Galera Therapeutics	N/A	N/A	-$59.08 million	($0.99)	-0.07

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Galectin Therapeutics and Galera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-184.63%
Galera Therapeutics	N/A	N/A	-116.47%

Volatility & Risk

Galectin Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.

Institutional & Insider Ownership

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 52.7% of Galectin Therapeutics shares are held by company insiders. Comparatively, 6.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Galectin Therapeutics beats Galera Therapeutics on 5 of the 9 factors compared between the two stocks.

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

About Galera Therapeutics

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.